Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033530 | 0.85 | RIPK1 (0.31) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL4371651 | 0.80 | KCNN4 (0.33) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL16192269 | 0.80 | RIPK1 (0.34) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL4367309 | 0.78 | RIPK1 (0.33) | SLC6A3KCNN4CYP3A4TDP1 | |
| SCHEMBL2879294 | 0.78 | TAAR1 (0.35) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL16192495 | 0.77 | TDP1 (0.38) | SLC6A4SLC6A3CYP3A4TDP1 | |
| SCHEMBL4374396 | 0.77 | RIPK1 (0.36) | KCNN4CYP3A4TDP1 | |
| SCHEMBL4370993 | 0.74 | RIPK1 (0.31) | — | |
| SCHEMBL4368006 | 0.74 | RIPK1 (0.35) | CYP2D6CYP1A2CYP3A4TDP1 | |
| SCHEMBL4370119 | 0.73 | RIPK1 (0.32) | SIGMAR1KCNN4CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2004-01-29 | — | — | US | claimed |
| EP-0949265-B1 | RADIOACTIVE TRANSITION METAL NITRIDE HETERO-COMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2003-05-07 | — | — | EP | claimed |
| US-20020048549-A1 | Radioactive transition metal nitride heterocomplex | DUATTI ADRIANO (IT) | 2002-04-25 | — | — | US | claimed |
| US-6270745-B1 | FROM A BIS(PHOSPHINOALKYL) SULFIDE OR AMINE | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2001-08-07 | — | — | US | claimed |
| EP-0949265-A1 | RADIOACTIVE TRANSITION METAL NITRIDE HETERO-COMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 1999-10-13 | — | — | EP | claimed |
| US-7445765-B2 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2008-11-04 | — | — | US | disclosed |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-0949265-B1 | RADIOACTIVE TRANSITION METAL NITRIDE HETERO-COMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20020048549-A1 | Radioactive transition metal nitride heterocomplex | DUATTI ADRIANO (IT) | 2002-04-25 | — | — | US | disclosed |
| US-6270745-B1 | FROM A BIS(PHOSPHINOALKYL) SULFIDE OR AMINE | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-0949265-A1 | RADIOACTIVE TRANSITION METAL NITRIDE HETERO-COMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020048549-A1 | Radioactive transition metal nitride heterocomplex | SHBG, GNRHR, PRMT5 | TAAR1 766/4885SLC6A2 1270/4885MAOA 2894/4885 |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | SHBG, TNNT2, TNNI3 | TAAR1 1529/4885SLC6A2 132/4885MAOA 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.